Publications by authors named "JaBreia Fanita James"
Article Synopsis
- Hidradenitis suppurativa (HS) primarily affects women and individuals of Black and biracial backgrounds, with adalimumab as the only FDA-approved treatment; ongoing trials aim to improve therapeutic options and ensure diverse participations.
- A systematic review of HS clinical trials revealed significant gaps in reporting race and ethnicity, as 31.6% of participants had missing data, with a majority being white (79.3%) and female (72.5%).
- Most studies excluded certain groups such as pediatric patients, pregnant women, and those with varying severity levels of HS, which might hinder treatment equity and access for underrepresented populations.
